Agilus Diagnostics, one of India’s largest diagnostic networks and a subsidiary of Fortis Healthcare Ltd., has announced the installation of the Illumina NovaSeq X at its Mumbai reference laboratory. With this milestone, Agilus significantly strengthens India’s capacity for large-scale next-generation sequencing (NGS). The launch event was attended by Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare; Dr. Anand K., Managing Director & CEO, Agilus Diagnostics Ltd.; and Mr. Deepak Narang, Chief Operating Officer, Agilus Diagnostics.
Genomics Driving the Future of Healthcare
Genomic technologies are rapidly transforming healthcare by enabling earlier diagnosis and delivering precise insights into complex diseases. Today, sequencing supports a broad spectrum of applications, including rare and inherited disorders, reproductive health, pharmacogenomics, infectious disease surveillance, and large-scale genome initiatives. As a result, genomics has become central to advancing personalized, preventive, and precision medicine.
NovaSeq X Enhances Molecular Testing at Scale
As per the press release, the addition of the NovaSeq X significantly strengthens Agilus Diagnostics’ molecular testing capabilities through high-throughput sequencing and scalable analytics. Moreover, its multi-omic capacity delivers rapid, high-resolution results across diverse clinical applications. By leveraging Agilus’ nationwide laboratory network, these advanced capabilities become accessible to clinicians and patients not only in metropolitan centres but also in emerging markets.
High-Throughput, High-Precision Clinical Sequencing
Powered by high-density flow cells and advanced automation, the NovaSeq X enables whole exome sequencing (WES), whole genome sequencing (WGS), and multi-omic analysis with exceptional speed and accuracy. Importantly, Agilus has deployed the platform for high-fidelity clinical decision-making rather than research alone. Consequently, physicians receive actionable molecular insights with faster turnaround times, supporting timely and informed patient care.
Leadership Perspectives on Precision Diagnostics
Commenting on the launch, Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, “Integrating advanced platforms like the Illumina NovaSeq X into clinical diagnostics is a pivotal step for India’s healthcare ecosystem. High-quality molecular insights are essential not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalised and preventive care. Agilus’ investment brings cutting-edge science closer to patients and equips clinicians with actionable information to improve outcomes across a wide range of conditions.”
Adding to this, Dr. Anand K., Managing Director & CEO, Agilus Diagnostics, said, “The NovaSeq X represents a major milestone in our precision diagnostics journey. It strengthens our multi-omic capabilities across genomics and proteomics, enabling faster, high-resolution insights that support personalised medicine. Ultimately, this advancement moves us closer to delivering truly predictive and individualized care for patients across India.”
Expanded Clinical Applications for Clinicians and Researchers
With enhanced sequencing capacity, clinicians and researchers can now access a wider range of advanced diagnostic applications. These include whole exome and whole genome sequencing for comprehensive variant detection, genetic evaluation of inherited and rare disorders, and reproductive and maternal health testing such as carrier screening and prenatal diagnostics. In addition, the platform supports pharmacogenomic assessments to guide drug response and dosing, infectious disease sequencing for pathogen tracking and antimicrobial resistance insights, and liquid biopsy-based circulating tumour DNA (ctDNA) analysis. Together, these capabilities also enable multi-omic studies for longitudinal disease monitoring and deeper biological understanding.
Translating Complex Data into Clinical Action
The NovaSeq X powers Agilus’ expanding portfolio of advanced assays, including proprietary liquid biopsy panels, rare disease testing workflows, reproductive genomics, pharmacogenomic profiling, infectious disease sequencing, and multi-omic studies. By integrating these outputs into established clinical pathways, Agilus transforms complex molecular data into clear, clinically actionable reports that support effective decision-making.
Advancing Precision and Predictive Healthcare in India
This strategic investment accelerates Agilus Diagnostics’ vision for precision diagnostics and predictive healthcare in India. With the NovaSeq X, Agilus positions itself among a select group of providers ready to lead the future of precision medicine—spanning population genomics, proteomic innovation, and longitudinal patient monitoring—while ensuring next-generation diagnostics remain scalable, clinically relevant, and accessible across the country.